Global Psychiatrists Market Report 2022: Rising Government Support for Mental Health Reforms is Expected to Propel Growth
December 30, 2022 06:28 ET
|
Research and Markets
Dublin, Dec. 30, 2022 (GLOBE NEWSWIRE) -- The "Psychiatrists Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
December 28, 2022 08:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Olanzapine Market Is Expected to Reach USD 2.2 Billion by 2031, Says Allied Market Research
December 01, 2022 04:56 ET
|
Allied Market Research
Portland, OR, Dec. 01, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global olanzapine market generated $1.8 billion in 2021, and is estimated to reach...
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022 08:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
August 22, 2022 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 09, 2022 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
When Medicine is Not Enough for Schizophrenia and Psychosis
June 30, 2022 09:00 ET
|
Brain & Behavior Research Foundation
New York, June 30, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “When Medicine is Not Enough for Schizophrenia and Psychosis” on Tuesday,...
VAGA Helps People Suffering with Poor Mental Health or Cognitive Decline Through Art Therapy
June 13, 2022 09:00 ET
|
Vaga
New York, June 13, 2022 (GLOBE NEWSWIRE) -- Mental health is a topic that has been under the spotlight in recent years, as people are realising that it is just as important as physical health and...
Behavioral Health Market to Cross Valuation of US$ 262 Bn by 2031; Growing Need for Treating Substance Abuse Disorders Underpins Abundant Avenues: TMR Study
June 06, 2022 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 06, 2022 (GLOBE NEWSWIRE) -- The global market study on behavioral health market is witnessing steady creation of lucrative opportunities on the back of...
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
May 04, 2022 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...